Subscribe to our monthly newsletter Subscribe

CINA-LVO

Avicenna.AI

The CINA-LVO solution is designed to automatically detect and prioritize acute large vessel occlusions on CTA.

Information source: Vendor
Last updated: July 9, 2024

General Information

General
Product name	CINA-LVO
Company	Avicenna.AI
Subspeciality	Neuro
Modality	CT
Disease targeted	Stroke
Key-features	Large vessel occlusion detection, notification
Suggested use	Before: adapting worklist order, flagging acute findings

Technical Specifications

Data characteristics
Population	Suspicion of stroke
Input	Brain CTA
Input format	DICOM
Output	bounding box, worklist order, notification
Output format	DICOM SC, GSPS
Technology
Integration	Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis	Automatically, right after the image acquisition
Processing time	10 - 60 seconds

Regulatory

Certification
CE	Certified, Class IIb , MDR
FDA	510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)	CINA is a radiological computer aided triage and notification software indicated for use in the analysis of (1) non-enhanced head CT images and (2) CT angiographies of the head. The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communicating suspected positive findings of (1) head CT images for Intracranial Hemorrhage (ICH) and (2) CT angiographies of the head for large vessel occlusion (LVO). CINA uses an artificial intelligence algorithm to analyze images and highlight cases with detected (1) ICH or (2) LVO on a standalone Web application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected ICH or LVO findings. Notifications include compressed preview images that are meant for informational purposes only, and are not intended for diagnostic use beyond notification. The device does not alter the original medical image, and it is not intended to be used as a diagnostic device. The results of CINA are intended to be used in conjunction with other patient information and based on professional judgment to assist with triage/prioritization of medical images. Notified clinicians are ultimately responsible for reviewing full images per the standard of care.

Market

Market presence
On market since	02-2020
Distribution channels	Eureka Clinical AI, Canon Automation Platform, Blackford, Tempus Pixel, Nuance PIN AI Marketplace, Sectra Amplifier Store, deepcOS, Incepto, CARPL.ai, Calantic
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Pay-per-use, Subscription
Based on	Number of installations, Number of analyses

Evidence

Evidence
Peer reviewed papers on performance	Duration and accuracy of automated stroke CT workflow with AI‑supported intracranial large vessel occlusion detection (read) Validation of an artificial intelligence-driven large vessel occlusion detection algorithm for acute ischemic stroke patients (read) Validation of a Deep Learning Tool in the Detection of Intracranial Hemorrhage and Large Vessel Occlusion (read)
Non-peer reviewed papers on performance
Other relevant papers